{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:46:32Z","timestamp":1792554392779,"version":"4.5.0"},"reference-count":299,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:00:00Z","timestamp":1416528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>This work provides a systematic review of the literature from January 2003 to April 2014 pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and offers recommendations for its management based on multidisciplinary international consensus. ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab). The incidence of ONJ is greatest in the oncology patient population (1% to 15%), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of ONJ is estimated at 0.001% to 0.01%, marginally higher than the incidence in the general population (&amp;lt;0.001%). New insights into the pathophysiology of ONJ include antiresorptive effects of BPs and Dmab, effects of BPs on gamma delta T-cells and on monocyte and macrophage function, as well as the role of local bacterial infection, inflammation, and necrosis. Advances in imaging include the use of cone beam computerized tomography assessing cortical and cancellous architecture with lower radiation exposure, magnetic resonance imaging, bone scanning, and positron emission tomography, although plain films often suffice. Other risk factors for ONJ include glucocorticoid use, maxillary or mandibular bone surgery, poor oral hygiene, chronic inflammation, diabetes mellitus, ill-fitting dentures, as well as other drugs, including antiangiogenic agents. Prevention strategies for ONJ include elimination or stabilization of oral disease prior to initiation of antiresorptive agents, as well as maintenance of good oral hygiene. In those patients at high risk for the development of ONJ, including cancer patients receiving high-dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage. Management of ONJ is based on the stage of the disease, size of the lesions, and the presence of contributing drug therapy and comorbidity. Conservative therapy includes topical antibiotic oral rinses and systemic antibiotic therapy. Localized surgical debridement is indicated in advanced nonresponsive disease and has been successful. Early data have suggested enhanced osseous wound healing with teriparatide in those without contraindications for its use. Experimental therapy includes bone marrow stem cell intralesional transplantation, low-level laser therapy, local platelet-derived growth factor application, hyperbaric oxygen, and tissue grafting. \u00a9 2014 American Society for Bone and Mineral Research \u00a9 2014 American Society for Bone and Mineral Research<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.2405","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T05:13:49Z","timestamp":1416546829000},"page":"3-23","source":"Crossref","is-referenced-by-count":1176,"title":["Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus"],"prefix":"10.1093","volume":"30","author":[{"given":"Aliya A","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archie","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie K","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"O'Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore L","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tetradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne N","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente L","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Al Dabagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Shawn","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K","family":"S\u00e1ndor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G","family":"Josse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El Rabbany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique D","family":"Pierroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Sulimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah P","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Compston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the International Task Force on Osteonecrosis of the Jaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,21]]},"reference":[{"key":"2024020319205981000_jbmr2405-bib-0001","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.080759","article-title":"Bisphosphonate associated osteonecrosis of the jaw","volume":"36","author":"Khan","year":"2009","journal-title":"J Rheumatol."},{"key":"2024020319205981000_jbmr2405-bib-0002","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","volume":"35","author":"Khan","year":"2008","journal-title":"J Rheumatol."},{"key":"2024020319205981000_jbmr2405-bib-0003","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2024020319205981000_jbmr2405-bib-0004","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0005","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0030-4220(93)90433-5","article-title":"Lingual mandibular sequestration and ulceration","volume":"75","author":"Peters","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol."},{"key":"2024020319205981000_jbmr2405-bib-0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.bdj.4801315","article-title":"Oral ulceration: a new unusual complication","volume":"192","author":"Scully","year":"2002","journal-title":"Br Dent J."},{"key":"2024020319205981000_jbmr2405-bib-0007","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1902\/jop.1997.68.8.758","article-title":"Spontaneous bony exposure: a report of 4 cases of idiopathic exposure and sequestration of alveolar bone","volume":"68","author":"Sonnier","year":"1997","journal-title":"J Periodontol."},{"key":"2024020319205981000_jbmr2405-bib-0008","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0009","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0011","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on Denosumab","volume":"68","author":"Aghaloo","year":"2010","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0013","doi-asserted-by":"crossref","first-page":"981","DOI":"10.14219\/jada.archive.2012.0323","article-title":"Denosumab-related osteonecrosis of the jaw","volume":"143","author":"Diz","year":"2012","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0014","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.joms.2008.01.038","article-title":"Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment","volume":"66","author":"Allen","year":"2008","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0016","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.joms.2010.05.090","article-title":"Lack of correlation between duration of osteonecrosis of the jaw and sequestra tissue morphology: what it tells us about the condition and what it means for future studies","volume":"68","author":"Allen","year":"2010","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0017","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.joms.2009.03.048","article-title":"Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-824X-5-1","article-title":"Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect","volume":"5","author":"Sharma","year":"2013","journal-title":"Vasc Cell."},{"key":"2024020319205981000_jbmr2405-bib-0019","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series","volume":"123","author":"Fedele","year":"2010","journal-title":"Am J Med."},{"key":"2024020319205981000_jbmr2405-bib-0020","first-page":"97","article-title":"Painful trigeminal neuropathy induced by oral bisphosphonate-related osteonecrosis of the jaw: a new etiology for the numb-chin syndrome","volume":"43","author":"Zadik","year":"2012","journal-title":"Quintessence Int."},{"key":"2024020319205981000_jbmr2405-bib-0021","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.joms.2008.09.028","article-title":"The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw","volume":"67","author":"Otto","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0022","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.joms.2010.10.055","article-title":"Preventive protocol for tooth extractions in patients treated with zoledronate: a case series","volume":"69","author":"Ferlito","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0023","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.joms.2010.07.026","article-title":"Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report","volume":"69","author":"Scoletta","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0024","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J Dent Res."},{"key":"2024020319205981000_jbmr2405-bib-0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.oraloncology.2011.11.004","article-title":"The Saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws","volume":"48","author":"Schubert","year":"2012","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0026","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.joms.2011.02.049","article-title":"Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion","volume":"70","author":"Fitzpatrick","year":"2012","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0028","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Thumbigere-Math","year":"2012","journal-title":"Am J Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0029","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3174\/ajnr.A0518","article-title":"Imaging findings of bisphosphonate-associated osteonecrosis of the jaws","volume":"28","author":"Phal","year":"2007","journal-title":"AJNR Am J Neuroradiol."},{"key":"2024020319205981000_jbmr2405-bib-0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijom.2010.11.006","article-title":"Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris","volume":"40","author":"Maurer","year":"2011","journal-title":"Int J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0032","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management","volume":"102","author":"Ruggiero","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0033","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw -2009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust Endod J."},{"key":"2024020319205981000_jbmr2405-bib-0034","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.oooo.2013.10.010","article-title":"Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system","volume":"117","author":"Schiodt","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0035","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg."},{"issue":"4","key":"2024020319205981000_jbmr2405-bib-0036","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2478\/v10019-010-0032-x","article-title":"Imaging findings in bisphosphonate-induced osteonecrosis of the jaws","volume":"44","author":"Popovic","year":"2010","journal-title":"Radiol Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.crad.2007.04.023","article-title":"Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients","volume":"63","author":"Bisdas","year":"2008","journal-title":"Clin Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0038","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","article-title":"Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0039","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.oooo.2012.08.444","article-title":"Metagenomic investigation of microbes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy","volume":"114","author":"Sedghizadeh","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00106-012-2554-6","article-title":"Bilateral bisphosphonate-associated of osteonecrosis the external ear canal : a rare case","volume":"60","author":"Bast","year":"2012","journal-title":"HNO."},{"key":"2024020319205981000_jbmr2405-bib-0041","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1097\/SCS.0b013e3182a24846","article-title":"Bisphosphonate-associated osteonecrosis of the external auditory canal","volume":"24","author":"Kharazmi","year":"2013","journal-title":"J Craniofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0042","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.bjoms.2013.02.013","article-title":"Bisphosphonate-associated osteonecrosis of the auditory canal","volume":"51","author":"Kharazmi","year":"2013","journal-title":"Br J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0043","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2141.2005.05833.x","article-title":"Bisphosphonate-associated osteonecrosis of the auditory canal","volume":"132","author":"Polizzotto","year":"2006","journal-title":"Br J Haematol"},{"key":"2024020319205981000_jbmr2405-bib-0044","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MAO.0b013e31827ca34d","article-title":"Osteonecrosis of the external auditory canal associated with oral bisphosphonate therapy: case report and literature review","volume":"34","author":"Salzman","year":"2013","journal-title":"Otol Neurotol."},{"issue":"Suppl 2","key":"2024020319205981000_jbmr2405-bib-0045","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1017\/S002221511300100X","article-title":"Bisphosphonate-associated osteonecrosis of the external auditory canal","volume":"127","author":"Wickham","year":"2013","journal-title":"J Laryngol Otol."},{"key":"2024020319205981000_jbmr2405-bib-0046","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00405-011-1496-z","article-title":"Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study","volume":"268","author":"Froelich","year":"2011","journal-title":"Eur Arch Otorhinolaryngol."},{"key":"2024020319205981000_jbmr2405-bib-0047","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","article-title":"Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people","volume":"139","author":"Cartsos","year":"2008","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0048","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/0022034510387795","article-title":"ONJ in two dental practice-based research network regions","volume":"90","author":"Fellows","year":"2011","journal-title":"J Dent Res."},{"key":"2024020319205981000_jbmr2405-bib-0049","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.joms.2007.09.019","article-title":"Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases","volume":"66","author":"Grant","year":"2008","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0050","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00198-009-1024-9","article-title":"Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia","volume":"21","author":"Hong","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024020319205981000_jbmr2405-bib-0051","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.diabres.2011.03.033","article-title":"Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes","volume":"93","author":"Iwamoto","year":"2011","journal-title":"Diabetes Res Clin Pract."},{"key":"2024020319205981000_jbmr2405-bib-0052","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0053","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00774-011-0299-z","article-title":"An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence","volume":"30","author":"Malden","year":"2012","journal-title":"J Bone Miner Metab."},{"key":"2024020319205981000_jbmr2405-bib-0054","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0055","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1038\/sj.bdj.2013.327","article-title":"A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital","volume":"214","author":"Taylor","year":"2013","journal-title":"Br Dent J."},{"key":"2024020319205981000_jbmr2405-bib-0056","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bone.2012.08.115","article-title":"Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan","volume":"51","author":"Yamazaki","year":"2012","journal-title":"Bone."},{"key":"2024020319205981000_jbmr2405-bib-0057","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14219\/jada.archive.2009.0019","article-title":"Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0058","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020319205981000_jbmr2405-bib-0059","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/qjmed\/hcs112","article-title":"Incidence of serious side effects with intravenous bisphosphonate: a clinical audit","volume":"105","author":"Powell","year":"2012","journal-title":"QJM."},{"key":"2024020319205981000_jbmr2405-bib-0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40261-012-0041-1","article-title":"Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice","volume":"33","author":"Sieber","year":"2013","journal-title":"Clin Drug Investig."},{"key":"2024020319205981000_jbmr2405-bib-0061","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/ncpendmet0348","article-title":"Osteonecrosis of the jaw\u2014a potential adverse effect of bisphosphonate treatment","volume":"2","author":"Felsenberg","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab."},{"key":"2024020319205981000_jbmr2405-bib-0062","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3899\/jrheum.100221","article-title":"Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons","volume":"38","author":"Khan","year":"2011","journal-title":"J Rheumatol."},{"key":"2024020319205981000_jbmr2405-bib-0063","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.joms.2011.02.093","article-title":"Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study","volume":"70","author":"Vestergaard","year":"2012","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0064","first-page":"691","article-title":"Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study","volume":"35","author":"Etminan","year":"2008","journal-title":"J Rheumatol."},{"key":"2024020319205981000_jbmr2405-bib-0065","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/pds.3292","article-title":"Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis","volume":"21","author":"Tennis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2024020319205981000_jbmr2405-bib-0066","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","article-title":"Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate","volume":"72","author":"Ulmner","year":"2014","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0067","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14219\/jada.archive.2008.0017","article-title":"Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial","volume":"139","author":"Grbic","year":"2008","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0068","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00198-007-0367-3","article-title":"Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis","volume":"18","author":"Devogelaer","year":"2007","journal-title":"Osteoporos Int."},{"key":"2024020319205981000_jbmr2405-bib-0069","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0070","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020319205981000_jbmr2405-bib-0071","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020319205981000_jbmr2405-bib-0072","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020319205981000_jbmr2405-bib-0073","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2006.02.011","article-title":"Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?","volume":"64","author":"Zavras","year":"2006","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0074","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00198-007-0502-1","article-title":"Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker","volume":"19","author":"Pazianas","year":"2008","journal-title":"Osteoporos Int."},{"key":"2024020319205981000_jbmr2405-bib-0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program","volume":"141","author":"Grbic","year":"2010","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0076","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone."},{"key":"2024020319205981000_jbmr2405-bib-0077","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med."},{"key":"2024020319205981000_jbmr2405-bib-0078","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet Gynecol."},{"key":"2024020319205981000_jbmr2405-bib-0079","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0080","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020319205981000_jbmr2405-bib-0081","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone."},{"issue":"1","key":"2024020319205981000_jbmr2405-bib-0082","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of Denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0083","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol."},{"key":"2024020319205981000_jbmr2405-bib-0084","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdl408","article-title":"Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis","volume":"18","author":"Aguiar","year":"2007","journal-title":"Ann Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest."},{"key":"2024020319205981000_jbmr2405-bib-0086","first-page":"3917","article-title":"Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies","volume":"33","author":"Assaf","year":"2013","journal-title":"Anticancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0087","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1308\/003588410X12699663903395","article-title":"Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital","volume":"92","author":"Baqain","year":"2010","journal-title":"Ann R Coll Surg Engl."},{"key":"2024020319205981000_jbmr2405-bib-0088","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0089","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12032-009-9195-y","article-title":"Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis","volume":"27","author":"Bonomi","year":"2010","journal-title":"Med Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1532\/IJH97.E0536","article-title":"Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients","volume":"83","author":"Capalbo","year":"2006","journal-title":"Int J Hematol."},{"key":"2024020319205981000_jbmr2405-bib-0091","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","article-title":"Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy","volume":"51","author":"Chang","year":"2012","journal-title":"Bone."},{"key":"2024020319205981000_jbmr2405-bib-0092","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.otohns.2006.11.008","article-title":"Stack BC Jr. Bisphosphonates and jaw osteonecrosis: the UAMS experience","volume":"136","author":"Clarke","year":"2007","journal-title":"Otolaryngol Head Neck Surg."},{"key":"2024020319205981000_jbmr2405-bib-0093","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica."},{"key":"2024020319205981000_jbmr2405-bib-0094","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","article-title":"Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy","volume":"13","author":"Estilo","year":"2008","journal-title":"Oncologist."},{"key":"2024020319205981000_jbmr2405-bib-0095","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years","volume":"10","author":"Guarneri","year":"2005","journal-title":"Oncologist."},{"key":"2024020319205981000_jbmr2405-bib-0096","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","article-title":"Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis","volume":"116","author":"Mauri","year":"2009","journal-title":"Breast Cancer Res Treat."},{"key":"2024020319205981000_jbmr2405-bib-0097","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/thy.2010.0169","article-title":"Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma","volume":"21","author":"Orita","year":"2011","journal-title":"Thyroid."},{"key":"2024020319205981000_jbmr2405-bib-0098","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0099","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.24119","article-title":"Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients","volume":"115","author":"Walter","year":"2009","journal-title":"Cancer."},{"key":"2024020319205981000_jbmr2405-bib-0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.breast.2012.09.012","article-title":"Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid","volume":"22","author":"Young","year":"2013","journal-title":"Breast."},{"key":"2024020319205981000_jbmr2405-bib-0101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.21912","article-title":"Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid","volume":"86","author":"Berenson","year":"2011","journal-title":"Am J Hematol."},{"key":"2024020319205981000_jbmr2405-bib-0102","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer."},{"key":"2024020319205981000_jbmr2405-bib-0103","doi-asserted-by":"crossref","first-page":"506","DOI":"10.14219\/jada.archive.2011.0220","article-title":"Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab","volume":"142","author":"Francini","year":"2011","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1399-0012.2011.01527.x","article-title":"Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation","volume":"26","author":"Ganguly","year":"2012","journal-title":"Clin Transplant."},{"key":"2024020319205981000_jbmr2405-bib-0105","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0106","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0107","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","article-title":"Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate","volume":"54","author":"Walter","year":"2008","journal-title":"Eur Urol."},{"key":"2024020319205981000_jbmr2405-bib-0108","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0109","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0111","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0112","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3816\/CLM.2008.n.013","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid","volume":"8","author":"Cafro","year":"2008","journal-title":"Clin Lymphoma Myeloma."},{"key":"2024020319205981000_jbmr2405-bib-0113","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology."},{"key":"2024020319205981000_jbmr2405-bib-0114","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","article-title":"Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01\u201304) for women with stage II\/III breast cancer","volume":"127","author":"Coleman","year":"2011","journal-title":"Breast Cancer Res Treat."},{"key":"2024020319205981000_jbmr2405-bib-0115","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med."},{"key":"2024020319205981000_jbmr2405-bib-0116","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia."},{"key":"2024020319205981000_jbmr2405-bib-0117","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3109\/07357900902783203","article-title":"Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer","volume":"27","author":"Crawford","year":"2009","journal-title":"Cancer Invest."},{"key":"2024020319205981000_jbmr2405-bib-0118","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0119","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.breast.2012.04.008","article-title":"Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis","volume":"21","author":"Ding","year":"2012","journal-title":"Breast."},{"key":"2024020319205981000_jbmr2405-bib-0120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet."},{"key":"2024020319205981000_jbmr2405-bib-0121","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90\u2009mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0122","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/00365590903295193","article-title":"Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw","volume":"43","author":"Haidar","year":"2009","journal-title":"Scand J Urol Nephrol."},{"key":"2024020319205981000_jbmr2405-bib-0123","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0124","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat."},{"key":"2024020319205981000_jbmr2405-bib-0125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1634\/theoncologist.2007-0159","article-title":"Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study","volume":"13","author":"Ibrahim","year":"2008","journal-title":"Oncologist."},{"issue":"3","key":"2024020319205981000_jbmr2405-bib-0126","first-page":"135","article-title":"Bisphosphonate (zoledronic acid) associated adverse events: single center experience","volume":"20","author":"Kucukzeybek","year":"2010","journal-title":"UHOD."},{"key":"2024020319205981000_jbmr2405-bib-0127","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00520-008-0484-3","article-title":"Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution","volume":"16","author":"La","year":"2008","journal-title":"Support Care Cancer."},{"key":"2024020319205981000_jbmr2405-bib-0128","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1111\/j.1464-410X.2012.11205.x","article-title":"Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel","volume":"110","author":"Miyazaki","year":"2012","journal-title":"BJU Int."},{"key":"2024020319205981000_jbmr2405-bib-0129","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet."},{"key":"2024020319205981000_jbmr2405-bib-0130","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer."},{"key":"2024020319205981000_jbmr2405-bib-0131","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tripleo.2011.02.037","article-title":"Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center","volume":"112","author":"Nicolatou-Galitis","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0132","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/02841860601185917","article-title":"Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis","volume":"46","author":"Ortega","year":"2007","journal-title":"Acta Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0133","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","article-title":"Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01\/04)","volume":"31","author":"Rathbone","year":"2013","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024020319205981000_jbmr2405-bib-0134","first-page":"30","article-title":"A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents","volume":"6","author":"Ria","year":"2013","journal-title":"Int J Clin Exp Med."},{"key":"2024020319205981000_jbmr2405-bib-0135","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/annonc\/mdl163","article-title":"Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer","volume":"17","author":"Sanna","year":"2006","journal-title":"Ann Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0136","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0137","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mds128","article-title":"Zoledronic acid in patients with stage IIIA\/B NSCLC: results of a randomized, phase III study","volume":"23","author":"Scagliotti","year":"2012","journal-title":"Ann Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0138","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/jpm.2006.0122","article-title":"Zoledronic acid treatment at home: safety data from an observational prospective trial","volume":"10","author":"Tassinari","year":"2007","journal-title":"J Palliat Med."},{"key":"2024020319205981000_jbmr2405-bib-0139","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0140","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0141","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton","year":"2008","journal-title":"Clin Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0142","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020319205981000_jbmr2405-bib-0143","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-160X-6-11","article-title":"Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients","volume":"6","author":"Walter","year":"2010","journal-title":"Head Face Med."},{"key":"2024020319205981000_jbmr2405-bib-0144","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.3747\/co.20.1055","article-title":"Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation","author":"Aviles","year":"2013","journal-title":"Curr Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0146","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer."},{"key":"2024020319205981000_jbmr2405-bib-0147","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000334456","article-title":"The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial","volume":"81","author":"Safra","year":"2011","journal-title":"Oncology."},{"issue":"3","key":"2024020319205981000_jbmr2405-bib-0148","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1359-6349(10)70055-0","article-title":"Zoledronic acid (ZOL) as add-on therapy in patients with tumour residuals after neoadjuvant chemotherapy for primary breast cancer -first interim safety analysis of the NATAN study (GBG 36). Abstract Book EBCC7 - European Breast Cancer Conference, Barcelona, Spain, 24\u201327 March 2010","volume":"8","author":"Von Minckwitz","year":"2010","journal-title":"EJC Suppl."},{"key":"2024020319205981000_jbmr2405-bib-0149","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet."},{"key":"2024020319205981000_jbmr2405-bib-0150","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol."},{"issue":"16","key":"2024020319205981000_jbmr2405-bib-0151","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer."},{"key":"2024020319205981000_jbmr2405-bib-0152","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00520-010-1061-0","article-title":"RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?","volume":"19","author":"Van den Wyngaert","year":"2011","journal-title":"Support Care Cancer."},{"issue":"1","key":"2024020319205981000_jbmr2405-bib-0153","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"2024020319205981000_jbmr2405-bib-0154","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/030089161109700411","article-title":"Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies","volume":"97","author":"Bantis","year":"2011","journal-title":"Tumori."},{"key":"2024020319205981000_jbmr2405-bib-0155","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0156","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/10428190600977690","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients","volume":"48","author":"Pozzi","year":"2007","journal-title":"Leuk Lymphoma."},{"key":"2024020319205981000_jbmr2405-bib-0157","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat."},{"key":"2024020319205981000_jbmr2405-bib-0158","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2006-07-033571","article-title":"Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone","volume":"108","author":"Tosi","year":"2006","journal-title":"Blood."},{"key":"2024020319205981000_jbmr2405-bib-0159","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00774-009-0047-9","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid","volume":"27","author":"Cetiner","year":"2009","journal-title":"J Bone Miner Metab."},{"key":"2024020319205981000_jbmr2405-bib-0160","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/BOR.0b013e32833ad677","article-title":"Bisphosphonate adverse effects, lessons from large databases","volume":"22","author":"Abrahamsen","year":"2010","journal-title":"Curr Opin Rheumatol."},{"key":"2024020319205981000_jbmr2405-bib-0161","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0162","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.2010.05771.x","article-title":"Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients","volume":"1218","author":"Hoff","year":"2011","journal-title":"Ann N Y Acad Sci."},{"key":"2024020319205981000_jbmr2405-bib-0163","first-page":"c85","article-title":"Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw","volume":"78","author":"Troeltzsch","year":"2012","journal-title":"J Can Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0164","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0165","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0166","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone."},{"key":"2024020319205981000_jbmr2405-bib-0167","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0168","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","article-title":"Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study","volume":"47","author":"Vescovi","year":"2011","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0169","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/iai.64.7.2371-2380.1996","article-title":"Bacterially induced bone destruction: mechanisms and misconceptions","volume":"64","author":"Nair","year":"1996","journal-title":"Infect Immun."},{"key":"2024020319205981000_jbmr2405-bib-0170","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/37.10.1095","article-title":"Surface-associated protein from Staphylococcus aureus stimulates osteoclastogenesis: possible role in S. aureus-induced bone pathology","volume":"37","author":"Meghji","year":"1998","journal-title":"Br J Rheumatol."},{"key":"2024020319205981000_jbmr2405-bib-0171","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00774-009-0090-6","article-title":"Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats","volume":"27","author":"Hikita","year":"2009","journal-title":"J Bone Miner Metab."},{"key":"2024020319205981000_jbmr2405-bib-0172","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1749-6632.2010.05835.x","article-title":"Potential pathophysiological mechanisms in osteonecrosis of the jaw","volume":"1218","author":"Landesberg","year":"2011","journal-title":"Ann N Y Acad Sci."},{"key":"2024020319205981000_jbmr2405-bib-0173","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.archoralbio.2010.11.003","article-title":"Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts","volume":"56","author":"Ravosa","year":"2011","journal-title":"Arch Oral Biol."},{"key":"2024020319205981000_jbmr2405-bib-0174","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00784-010-0507-6","article-title":"The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes\u2014in vitro study","volume":"16","author":"Pabst","year":"2012","journal-title":"Clin Oral Investig."},{"key":"2024020319205981000_jbmr2405-bib-0175","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1078-0432.CCR-10-1614","article-title":"Effect of zoledronate on oral wound healing in rats","volume":"17","author":"Yamashita","year":"2011","journal-title":"Clin Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0176","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1601-0825.2010.01739.x","article-title":"In vivo effects of zoledronic acid on oral mucosal epithelial cells","volume":"17","author":"Allam","year":"2011","journal-title":"Oral Dis."},{"key":"2024020319205981000_jbmr2405-bib-0177","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0178","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0179","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res."},{"key":"2024020319205981000_jbmr2405-bib-0180","first-page":"358","article-title":"Animal models of osteonecrosis of the jaw","volume":"7","author":"Allen","year":"2007","journal-title":"J Musculoskelet Neuronal Interact."},{"key":"2024020319205981000_jbmr2405-bib-0181","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000151371","article-title":"Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench","volume":"189","author":"Allen","year":"2009","journal-title":"Cells Tissues Organs."},{"key":"2024020319205981000_jbmr2405-bib-0182","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone."},{"key":"2024020319205981000_jbmr2405-bib-0183","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J Oral Pathol Med."},{"key":"2024020319205981000_jbmr2405-bib-0184","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jcb.24301","article-title":"The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches","volume":"114","author":"Soki","year":"2013","journal-title":"J Cell Biochem."},{"key":"2024020319205981000_jbmr2405-bib-0185","first-page":"364","article-title":"Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw","volume":"3","author":"Marini","year":"2011","journal-title":"Front Biosci (Elite Ed)."},{"key":"2024020319205981000_jbmr2405-bib-0186","first-page":"579","article-title":"A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer","volume":"6","author":"English","year":"2010","journal-title":"Ther Clin Risk Manag."},{"key":"2024020319205981000_jbmr2405-bib-0187","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood."},{"key":"2024020319205981000_jbmr2405-bib-0188","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijom.2011.02.002","article-title":"Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw","volume":"40","author":"Katz","year":"2011","journal-title":"Int J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0189","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","article-title":"Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3","volume":"17","author":"Nicoletti","year":"2012","journal-title":"Oncologist."},{"key":"2024020319205981000_jbmr2405-bib-0190","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.joms.2010.05.003","article-title":"Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure","volume":"68","author":"Hutchinson","year":"2010","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0191","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.048785","article-title":"Bone scintigraphy and SPECT\/CT of bisphosphonate-induced osteonecrosis of the jaw","volume":"50","author":"Dore","year":"2009","journal-title":"J Nucl Med."},{"key":"2024020319205981000_jbmr2405-bib-0192","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.tripleo.2009.12.005","article-title":"Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws","volume":"109","author":"Treister","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0193","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00784-009-0293-1","article-title":"Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study","volume":"14","author":"Stockmann","year":"2010","journal-title":"Clin Oral Investig"},{"key":"2024020319205981000_jbmr2405-bib-0194","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1259\/dmfr\/14636637","article-title":"Fractal dimension evaluation of cone beam computed tomography in patients with bisphosphonate-associated osteonecrosis","volume":"40","author":"Torres","year":"2011","journal-title":"Dentomaxillofac Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.joms.2008.12.002","article-title":"Imaging findings in bisphosphonate-related osteonecrosis of jaws","volume":"67","author":"Arce","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0196","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.joms.2009.03.005","article-title":"Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator","volume":"67","author":"O'Ryan","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0197","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1259\/dmfr\/27458726","article-title":"Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws","volume":"35","author":"Chiandussi","year":"2006","journal-title":"Dentomaxillofac Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0198","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11282-013-0135-3","article-title":"Radiographic findings of bisphosphonate-related osteomyelitis of the jaw: investigation of the diagnostic points by comparison with radiation osteomyelitis, suppurative osteomyelitis, and diffuse sclerosing osteomyelitis","volume":"29","author":"Suei","year":"2013","journal-title":"Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0199","volume-title":"Oral radiology","author":"White","year":"2008","edition":"6th ed"},{"key":"2024020319205981000_jbmr2405-bib-0200","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tripleo.2007.01.040","article-title":"Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer","volume":"104","author":"Bianchi","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0201","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tripleo.2007.08.040","article-title":"Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology","volume":"105","author":"Bedogni","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00784-009-0311-3","article-title":"Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation","volume":"14","author":"Elad","year":"2010","journal-title":"Clin Oral Investig."},{"key":"2024020319205981000_jbmr2405-bib-0203","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/RCT.0b013e318227a81d","article-title":"Bone-within-bone appearance: a red flag for biphosphonate-associated osteonecrosis of the jaw","volume":"35","author":"Fatterpekar","year":"2011","journal-title":"J Comput Assist Tomogr."},{"key":"2024020319205981000_jbmr2405-bib-0204","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11282-012-0114-0","article-title":"Recognition of bisphosphonate-related osteonecrosis of the jaw among oral and maxillofacial radiologists: results from a questionnaire-based survey in Japan","volume":"29","author":"Taguchi","year":"2013","journal-title":"Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0205","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.joms.2008.02.012","article-title":"Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?","volume":"66","author":"Junquera","year":"2008","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0206","first-page":"27","article-title":"Cone beam computed tomography in the diagnosis of dental disease","volume":"38","author":"Tetradis","year":"2010","journal-title":"J Calif Dent Assoc."},{"issue":"Suppl 1","key":"2024020319205981000_jbmr2405-bib-0207","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1834-7819.2011.01657.x","article-title":"Maxillofacial cone beam computed tomography: essence elements steps to interpretation","volume":"57","author":"Scarfe","year":"2012","journal-title":"Aust Dent J."},{"key":"2024020319205981000_jbmr2405-bib-0208","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.oooo.2011.11.011","article-title":"Mandibular cortical bone evaluation on cone beam computed tomography images of patients with bisphosphonate-related osteonecrosis of the jaw","volume":"113","author":"Torres","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0209","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.oooo.2012.08.458","article-title":"Prevalence of cone beam computed tomography imaging findings according to the clinical stage of bisphosphonate-related osteonecrosis of the jaw","volume":"114","author":"Wilde","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0210","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/RCT.0b013e31817e4986","article-title":"Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings","volume":"33","author":"Krishnan","year":"2009","journal-title":"J Comput Assist Tomogr."},{"issue":"2","key":"2024020319205981000_jbmr2405-bib-0211","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11282-013-0124-6","article-title":"Role of magnetic resonance imaging in diagnosis of bisphosphonate-related osteonecrosis of the jaw","volume":"29","author":"Ariji","year":"2013","journal-title":"Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0212","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2214\/AJR.07.3045","article-title":"MRI of mandibular osteonecrosis secondary to bisphosphonates","volume":"190","author":"Garcia-Ferrer","year":"2008","journal-title":"AJR Am J Roentgenol."},{"key":"2024020319205981000_jbmr2405-bib-0213","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/RLU.0b013e3181feeb72","article-title":"Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw","volume":"36","author":"Van den Wyngaert","year":"2011","journal-title":"Clin Nucl Med."},{"key":"2024020319205981000_jbmr2405-bib-0214","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00277-007-0263-0","article-title":"Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis","volume":"86","author":"Catalano","year":"2007","journal-title":"Ann Hematol."},{"key":"2024020319205981000_jbmr2405-bib-0215","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0039-1697848","article-title":"Invasive ductal carcinoma with multiple metastases to facial and cranial bones: a case report","volume":"4","author":"Ertas","year":"2010","journal-title":"Eur J Dent."},{"key":"2024020319205981000_jbmr2405-bib-0216","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00003072-199407000-00020","article-title":"Incidental finding of periodontal disease on bone scan","volume":"19","author":"Myers","year":"1994","journal-title":"Clin Nucl Med."},{"key":"2024020319205981000_jbmr2405-bib-0217","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.tripleo.2008.09.019","article-title":"Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw","volume":"107","author":"Wilde","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0218","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0219","first-page":"137","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates","volume":"20","author":"Ripamonti","year":"2009","journal-title":"The experience of the National Cancer Institute of Milan Ann Oncol"},{"key":"2024020319205981000_jbmr2405-bib-0220","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bone.2007.08.025","article-title":"Bisphosphonate-associated osteonecrosis can hide jaw metastases","volume":"41","author":"Bedogni","year":"2007","journal-title":"Bone."},{"key":"2024020319205981000_jbmr2405-bib-0221","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejso.2009.12.003","article-title":"Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists","volume":"36","author":"Chaturvedi","year":"2010","journal-title":"Eur J Surg Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0222","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1148\/rg.297095050","article-title":"Bisphosphonate-related osteonecrosis of the jaw: a pictorial review","volume":"29","author":"Morag","year":"2009","journal-title":"Radiographics."},{"key":"2024020319205981000_jbmr2405-bib-0223","first-page":"1304","article-title":"American Dental Association Council on Scientific Affairs. The use of dental radiographs: update and recommendations","volume":"137","year":"2006","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0224","first-page":"37","article-title":"American Association of Endodontists;American Academy of Oral and Maxillofacial Radiography. AAE and AAOMR joint position statement. Use of cone-beam-computed tomography in endodontics","volume":"78","year":"2011","journal-title":"Pa Dent J (Harrisb)."},{"key":"2024020319205981000_jbmr2405-bib-0225","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.oooo.2012.03.005","article-title":"Position statement of the American Academy of Oral and Maxillofacial Radiology on selection criteria for the use of radiology in dental implantology with emphasis on cone beam computed tomography","volume":"113","author":"Tyndall","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"2024020319205981000_jbmr2405-bib-0226"},{"key":"2024020319205981000_jbmr2405-bib-0227","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0228","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0229","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0501.2010.01965.x","article-title":"Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?","volume":"22","author":"Kwon","year":"2011","journal-title":"Clin Oral Implants Res."},{"key":"2024020319205981000_jbmr2405-bib-0231","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10103-011-0974-2","article-title":"Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?","volume":"26","author":"Atalay","year":"2011","journal-title":"Lasers Med Sci."},{"key":"2024020319205981000_jbmr2405-bib-0232","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0233","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ID.0b013e3181cec8bc","article-title":"CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study","volume":"19","author":"Lee","year":"2010","journal-title":"Implant Dent."},{"key":"2024020319205981000_jbmr2405-bib-0234","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11845-011-0790-5","article-title":"A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?","volume":"181","author":"O'Connell","year":"2012","journal-title":"Ir J Med Sci."},{"key":"2024020319205981000_jbmr2405-bib-0235","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.joms.2011.12.028","article-title":"Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases","volume":"70","author":"Morris","year":"2012","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0236","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tripleo.2008.01.033","article-title":"Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws","volume":"106","author":"Lehrer","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0237","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.joms.2008.09.015","article-title":"Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene","volume":"67","author":"Lehrer","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0238","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0239","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma."},{"key":"2024020319205981000_jbmr2405-bib-0240","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1834-7819.2008.00078.x","article-title":"The oral health status of patients on oral bisphosphonates for osteoporosis","volume":"53","author":"Kunchur","year":"2008","journal-title":"Aust Dent J."},{"key":"2024020319205981000_jbmr2405-bib-0241","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.joms.2009.07.068","article-title":"Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series","volume":"68","author":"Lodi","year":"2010","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0242","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.oraloncology.2011.12.004","article-title":"Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases","volume":"48","author":"Mozzati","year":"2012","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0243","first-page":"b147","article-title":"Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients","volume":"77","author":"Bonacina","year":"2011","journal-title":"J Can Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0244","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.joms.2013.01.006","article-title":"Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol","volume":"71","author":"Scoletta","year":"2013","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0245","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc."},{"key":"2024020319205981000_jbmr2405-bib-0246","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.tripleo.2011.07.004","article-title":"A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws","volume":"112","author":"Moretti","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0247","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1601-0825.2011.01848.x","article-title":"Antibiotic effects on bacterial profile in osteonecrosis of the jaw","volume":"18","author":"Ji","year":"2012","journal-title":"Oral Dis."},{"key":"2024020319205981000_jbmr2405-bib-0248","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0714.2011.01095.x","article-title":"Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome","volume":"41","author":"Fortuna","year":"2012","journal-title":"J Oral Pathol Med."},{"key":"2024020319205981000_jbmr2405-bib-0249","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","volume":"363","author":"Bashutski","year":"2010","journal-title":"N Engl J Med."},{"key":"2024020319205981000_jbmr2405-bib-0250","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tripleo.2011.04.020","article-title":"A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution","volume":"112","author":"Subramanian","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0251","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","article-title":"Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1\u201334)]","volume":"65","author":"Harper","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0252","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.081176","article-title":"Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1\u201334)] therapy","volume":"36","author":"Lau","year":"2009","journal-title":"J Rheumatol."},{"key":"2024020319205981000_jbmr2405-bib-0253","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMc1002684","article-title":"Teriparatide therapy for alendronate-associated osteonecrosis of the jaw","volume":"363","author":"Cheung","year":"2010","journal-title":"N Engl J Med."},{"key":"2024020319205981000_jbmr2405-bib-0254","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hed.21380","article-title":"Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy","volume":"33","author":"Lee","year":"2011","journal-title":"Head Neck."},{"key":"2024020319205981000_jbmr2405-bib-0255","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1754-4505.2009.00128.x","article-title":"Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report","volume":"30","author":"Narongroeknawin","year":"2010","journal-title":"Spec Care Dentist."},{"key":"2024020319205981000_jbmr2405-bib-0256","first-page":"547","article-title":"Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis","volume":"32","author":"Iwamoto","year":"2012","journal-title":"Clin Drug Investig."},{"key":"2024020319205981000_jbmr2405-bib-0257","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.oraloncology.2011.01.002","article-title":"Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study","volume":"47","author":"Ripamonti","year":"2011","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0258","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1746-160X-7-16","article-title":"Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw","volume":"7","author":"Cella","year":"2011","journal-title":"Head Face Med."},{"key":"2024020319205981000_jbmr2405-bib-0259","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tripleo.2010.05.067","article-title":"Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series","volume":"110","author":"Epstein","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0260","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.oraloncology.2010.12.003","article-title":"Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw","volume":"47","author":"Ziebart","year":"2011","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0261","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10103-009-0687-y","article-title":"Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT)","volume":"25","author":"Vescovi","year":"2010","journal-title":"Lasers Med Sci."},{"key":"2024020319205981000_jbmr2405-bib-0262","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0714.2011.01091.x","article-title":"Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients","volume":"41","author":"Vescovi","year":"2012","journal-title":"J Oral Pathol Med."},{"key":"2024020319205981000_jbmr2405-bib-0263","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","article-title":"The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw","volume":"111","author":"Wilde","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2024020319205981000_jbmr2405-bib-0264","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00432-010-0953-1","article-title":"Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws","volume":"137","author":"Mucke","year":"2011","journal-title":"J Cancer Res Clin Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0265","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","article-title":"Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab","volume":"11","author":"Ngamphaiboon","year":"2011","journal-title":"Clin Breast Cancer."},{"key":"2024020319205981000_jbmr2405-bib-0266","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.oraloncology.2011.08.010","article-title":"Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study","volume":"48","author":"Martins","year":"2012","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0267","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.joms.2010.07.014","article-title":"Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study","volume":"69","author":"Pautke","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0268","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.joms.2010.06.200","article-title":"Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw","volume":"69","author":"Hoefert","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0269","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/hed.21708","article-title":"Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"34","author":"Wutzl","year":"2012","journal-title":"Head Neck."},{"key":"2024020319205981000_jbmr2405-bib-0270","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.oraloncology.2011.02.024","article-title":"Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis","volume":"47","author":"Bedogni","year":"2011","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0271","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","article-title":"What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics","volume":"70","author":"Freiberger","year":"2012","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0272","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita","year":"2012","journal-title":"J Evid Based Dent Pract."},{"key":"2024020319205981000_jbmr2405-bib-0273","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2024020319205981000_jbmr2405-bib-0274","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0275","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2008.04.013","article-title":"Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients","volume":"45","author":"Sonis","year":"2009","journal-title":"Oral Oncol."},{"key":"2024020319205981000_jbmr2405-bib-0276","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jbmr.23","article-title":"Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats","volume":"25","author":"Hokugo","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0277","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/iep.12007","article-title":"Marcantonio E Jr. Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents","volume":"94","author":"Conte","year":"2013","journal-title":"Int J Exp Pathol."},{"key":"2024020319205981000_jbmr2405-bib-0278","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijom.2013.02.007","article-title":"Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model","volume":"42","author":"Abtahi","year":"2013","journal-title":"Int J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0279","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0765.1981.tb00995.x","article-title":"The progress of the periodontal syndrome in the rice cat. II. The effects of a diphosphonate on the periodontium","volume":"16","author":"Gotcher","year":"1981","journal-title":"J Periodontal Res."},{"key":"2024020319205981000_jbmr2405-bib-0280","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1600-0714.2011.01125.x","article-title":"Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone","volume":"41","author":"Abtahi","year":"2012","journal-title":"J Oral Pathol Med"},{"key":"2024020319205981000_jbmr2405-bib-0281","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.4317\/medoral.17150","article-title":"Extraction socket healing in rats treated with bisphosphonate: animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients","volume":"16","author":"Ali-Erdem","year":"2011","journal-title":"Med Oral Patol Oral Cir Bucal."},{"key":"2024020319205981000_jbmr2405-bib-0282","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","article-title":"Bisphosphonates cause osteonecrosis of the jaw-like disease in mice","volume":"177","author":"Bi","year":"2010","journal-title":"Am J Pathol."},{"key":"2024020319205981000_jbmr2405-bib-0283","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1600-0714.2010.00927.x","article-title":"An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats","volume":"39","author":"Lopez-Jornet","year":"2010","journal-title":"J Oral Pathol Med."},{"key":"2024020319205981000_jbmr2405-bib-0284","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0285","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bone.2012.04.020","article-title":"Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model","volume":"51","author":"Pautke","year":"2012","journal-title":"Bone."},{"key":"2024020319205981000_jbmr2405-bib-0286","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.joms.2012.11.016","article-title":"Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone","volume":"71","author":"Allen","year":"2013","journal-title":"J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0287","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/jbmr.1894","article-title":"Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice","volume":"28","author":"Kang","year":"2013","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0288","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-010-1268-4","article-title":"Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs","volume":"22","author":"Allen","year":"2011","journal-title":"Osteoporos Int."},{"issue":"4","key":"2024020319205981000_jbmr2405-bib-0289","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jbmr.2097","article-title":"RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease","volume":"29","author":"Aghaloo","year":"2014","journal-title":"J Bone Miner Res."},{"key":"2024020319205981000_jbmr2405-bib-0290","doi-asserted-by":"crossref","first-page":"6305s","DOI":"10.1158\/1078-0432.CCR-06-1157","article-title":"Future treatment of bone metastases","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0291","doi-asserted-by":"crossref","first-page":"6209s","DOI":"10.1158\/1078-0432.CCR-06-1213","article-title":"Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res."},{"key":"2024020319205981000_jbmr2405-bib-0292","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1834-7819.2003.tb00011.x","article-title":"Oral ulceration with bone sequestration","volume":"48","author":"Farah","year":"2003","journal-title":"Aust Dent J."},{"key":"2024020319205981000_jbmr2405-bib-0293","first-page":"40","article-title":"Oral maxillofacial pathology case of the month. Lingual mandibular sequestration ulceration","volume":"34","author":"Flaitz","year":"2000","journal-title":"Tex Dent J."},{"key":"2024020319205981000_jbmr2405-bib-0294","first-page":"206","article-title":"Oral maxillofacial pathology case of the month. Lingual mandibular sequestration with ulceration","volume":"198\u20139","author":"Kessler","year":"2005","journal-title":"Tex Dent J."},{"key":"2024020319205981000_jbmr2405-bib-0295","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bjoms.2005.05.012","article-title":"Extensive maxillary sequestration resulting from mucormycosis","volume":"43","author":"Huang","year":"2005","journal-title":"Br J Oral Maxillofac Surg."},{"key":"2024020319205981000_jbmr2405-bib-0296","doi-asserted-by":"crossref","first-page":"573","DOI":"10.12968\/denu.2007.34.9.573","article-title":"Lingual mucosal ulceration with mandibular sequestration","volume":"34","author":"Jackson","year":"2007","journal-title":"Dent Update."},{"issue":"9","key":"2024020319205981000_jbmr2405-bib-0297","first-page":"642","article-title":"Lingual mucosal ulceration with mandibular sequestration (Dent Update 2007;34: 573\u2013577)","volume":"35","author":"Dhanrajani","year":"2008","journal-title":"Dent Update."},{"key":"2024020319205981000_jbmr2405-bib-0298","first-page":"395","article-title":"An unusual case of total maxillary sequestration in a diabetic patient","volume":"37","author":"Akinmoladun","year":"2008","journal-title":"Afr J Med Med Sci."},{"key":"2024020319205981000_jbmr2405-bib-0299","volume-title":"Oral and maxillofacial pathology","author":"Neville","year":"2009","edition":"3rd ed"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2405","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/1\/3\/56569103\/jbmr2405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/1\/3\/56569103\/jbmr2405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:53:16Z","timestamp":1710327196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/30\/1\/3-23\/7599344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,21]]},"references-count":299,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,11,21]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2405","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725243862.793505492","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,1,1]]},"published":{"date-parts":[[2014,11,21]]}}}